S-1 plus cisplatin: Another option in the treatment of advanced head and neck cancer?

Expert Review of Anticancer Therapy

Volumn 10, Issue 5, 2010, Pages 659-662

  Yoon, Dok Hyun ^a   Kim, Sung Bae ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Advanced head and neck cancer; Cisplatin; Phase I; Phase II; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL;

ADVANCED CANCER; ANOREXIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; GENETIC HETEROGENEITY; HEAD AND NECK CANCER; HUMAN; METASTASIS; NAUSEA; NEUTROPENIA; NOTE; OVERALL SURVIVAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG COMBINATIONS; HEAD AND NECK NEOPLASMS; HUMANS; OXONIC ACID; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 77952505635     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.45     Document Type: Note

References (31)

1. Kish J, Drelichman A, Jacobs J et al. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat. Rep. 66 (3), 471-474 (1982).
2. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 98 (11), 1205-1211 (1988).
3. Vokes EE, Mick R, Lester EP, Panje WR, Weichselbaum RR. Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. J. Clin. Oncol. 9 (8), 1376-1384 (1991).
4. Choksi AJ, Hong WK, Dimery IW, James P, Guillamondegui OM, Byers RM. Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma. Cancer 61 (5), 909-912 (1988).
5. O'Brien M, Schofield JB, Lorentzos A et al. The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck. Eur. J. Cancer B Oral Oncol. 30B (4), 265-267 (1994).
6. Clavel M, Vermorken JB, Cognetti F et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A Phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann. Oncol. 5 (6), 521-526 (1994).
7. Paccagnella A, Pappagallo GL, Segati R et al. Response and toxicity of cisplatin and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck. Am. J. Clin. Oncol. 13 (3), 194-198 (1990).
8. Shirasaka T, Shimamato Y, Ohshimo H et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7 (5), 548-557 (1996).
9. Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn. J. Cancer Res. 78 (7), 748-755 (1987).
10. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 53 (17), 4004-4009 (1993).
11. Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD, Fukushima M. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int. J. Mol. Med. 22 (6), 709-716 (2008).
12. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late Phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer 34 (11), 1715-1720 (1998).
13. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58 (3), 191-197 (2000).
14. Ohtsu A, Baba H, Sakata Y et al. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br. J. Cancer 83 (2), 141-145 (2000).
15. Okusaka T, Funakoshi A, Furuse J et al. A late Phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 61 (4), 615-621 (2008).
16. Kawahara M, Furuse K, Segawa Y et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br. J. Cancer 85 (7), 939-943 (2001). (Pubitemid 33015993)
17. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. [Early Phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)]. Gan. To. Kagaku. Ryoho. 25 (8), 1151-1158 (1998).
18. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. [Late Phase II study of S-1 in patients with advanced head and neck cancer]. Gan. To. Kagaku. Ryoho. 28 (10), 1381-1390 (2001).
19. Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial. Lancet Oncol. 9 (3), 215-221 (2008).
20. Ajani JA, Faust J, Ikeda K et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J. Clin. Oncol. 23 (28), 6957-6965 (2005).
21. Lee JL, Kang HJ, Kang YK et al. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother. Pharmacol. 61 (5), 837-845 (2008).
22. Sato Y, Kondo H, Honda K et al. A Phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen. Int. J. Clin. Oncol. 10 (1), 40-44 (2005).
23. Choi YJ, Chung JS, Shin HJ et al. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. J. Laryngol. Otol. 122 (8), 848-853 (2008). A Phase II trial of S-1 plus cisplatin as induction chemotherapy in treatment of locally advanced head and neck cancer, supporting the feasibility of the regimen.
24. Watanabe A, Taniguchi M, Yamashita T et al. Phase I/II study of S-1 combined with carboplatin in recurrent and/or metastatic head and neck cancer as outpatient chemotherapy. Head Neck 28 (7), 620-625 (2006).
25. Kodaira T, Fuwa N, Tachibana H, Hidano S. Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. AntiCancer Res. 26 (3B), 2265-2268 (2006).
26. Fujii M, Tomita K, Nishijima W et al. Phase I/II study of S-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer. Jpn. J. Clin. Oncol. 40 (3), 214-221 (2010).
27. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl J. Med. 357 (17), 1705-1715 (2007). The first Phase III trial (TAX 324) demonstrating the efficacy of a docetaxelcontaining triplet regimen (TPF) as induction chemotherapy, followed by concurrent chemoradiotherapy, in treatment of patients with locally advanced head and neck cancer.
28. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl J. Med. 357 (17), 1695-1704 (2007). The first Phase III trial (EORTC 24791/TAX 323) demonstrating the efficacy of a docetaxel-containing triplet regimen (TPF) as induction chemotherapy, followed by definitive radiotherapy, in treatment of patients with locally advanced head and neck cancer.
29. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. 23 (34), 8636-8645 (2005).
30. Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol. 20 (4), 666-673 (2009).
31. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359 (11), 1116-1127 (2008). A pivotal trial (EXTREME), being the first to show survival benefit of a targeted agent, cetuximab, in the treatment of patients with advanced head and neck cancer.